ProPharma Integrated into Evotec Services Division
Evotec AG announced that ProPharma Limited, its formulation subsidiary based in Glasgow, Scotland, will do business under the Evotec brand from the 1st of September 2005. ProPharma will be integrated into the Evotec services Division over the coming months.
Evotec has been the majority shareholder in ProPharma since it was formed as a spin-out enterprise from the University of Strathclyde in Glasgow, Scotland, in 2000. Evotec invested start-up capital and have continued to provide investment since then to support the successful expansion of the business.
The strategic integration of ProPharma comes as a result of the growing synergy between the pharmaceutical development services offered by both Evotec and ProPharma. This will combine Evotec's expertise in cGMP manufacture of active pharmaceutical ingredients with Pro- Pharma's expertise in pharmaceutical formulation development and the small-scale sterile manufacture of pharmaceuticals for use in clinical trials. Evotec will therefore offer a more comprehensive range of services to its pharmaceutical and biotechnology company clients in order to drive their candidate pharmaceuticals along the drug development pathway.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Thermo Scientific Orbitrap Exploris | Orbitrap mass spectrometers | Thermo Fisher Scientific
Promega Corporation and FUJIFILM Cellular Dynamics Announce Strategic Collaboration to Advance Novel Assay Development - New licensing agreement will deliver luminescent reporter technology into iPSCs
Novartis study shows QTI571 significantly improved walking distance in patients with life-threatening pulmonary arterial hypertension
Human Genome Sciences initiates randomized Phase 2 clinical trial of HGS-ETR1 in combination with Bortezomib

Bioform Technologies - Vancouver, BC, Canada
